There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Acceleron Pharma (XLRN) and Milestone Scientific (MLSS) with bullish sentiments.
Acceleron Pharma (XLRN)
In a report released today, Leland Gershell from Oppenheimer maintained a Buy rating on Acceleron Pharma, with a price target of $126.00. The company’s shares closed last Friday at $108.27, close to its 52-week high of $114.87.
According to TipRanks.com, Gershell is a 2-star analyst with an average return of 0.7% and a 39.7% success rate. Gershell covers the Healthcare sector, focusing on stocks such as Milestone Pharmaceuticals, BioMarin Pharmaceutical, and Corbus Pharmaceuticals.
Acceleron Pharma has an analyst consensus of Strong Buy, with a price target consensus of $128.50, which is a 13.5% upside from current levels. In a report issued on September 24, Raymond James also maintained a Buy rating on the stock.
See today’s analyst top recommended stocks >>
Milestone Scientific (MLSS)
Maxim Group analyst Anthony Vendetti reiterated a Buy rating on Milestone Scientific yesterday and set a price target of $4.00. The company’s shares closed last Friday at $1.57.
According to TipRanks.com, Vendetti is a 4-star analyst with an average return of 5.2% and a 44.3% success rate. Vendetti covers the Healthcare sector, focusing on stocks such as Ra Medical Systems, Sensus Healthcare, and CHF Solutions.
Milestone Scientific has an analyst consensus of Moderate Buy, with a price target consensus of $4.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
